Dr. Elyse Watkins
Purpose: The purpose of this article is to review the current treatment for Eosinophilic Esophagitis (EoE) and discuss Dupilumab as a newly emerging therapy.
Method: A PubMed literature review for high-quality studies was performed to evaluate if Dupilumab is effective in treating adults with Eosinophilic esophagitis was conducted. The search terms used were; eosinophilic esophagitis treatment, diagnosis, and emerging therapy for eosinophilic esophagitis. The search retrieved twelve pertinent articles.
Results: Evidence-based research demonstrated the efficacy of Dupilumab in adults with active eosinophilic esophagitis in a randomized- controlled phase II trial.
Conclusion: Dupilumab, an antibody that targets the common α-chain of the IL-13 and IL-4 receptor, recently achieved an orphan designation for the treatment of EoE. In a phase II trial of patients with active EoE, dupilumab was shown to significantly reduce symptoms of dysphagia, histologic features of the disease, as well as a reduction in abnormal endoscopic features compared with placebo. During the trial Dupilumab increased esophageal distensibility and was generally well-tolerated, this promising new treatment may soon be the first FDA approved injectable medication for patients with EoE.
Keywords: adults, active eosinophilic esophagitis, and treatment.
"Emerging Therapies in Eosinophilic Esophagitis,"
Lynchburg Journal of Medical Science: Vol. 3
, Article 4.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol3/iss2/4
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.